Serum tryptase in allergic rhinitis: effect of cetirizine treatment.

Activated mast cells release a large range of potent mediators of allergic inflammation, including proteases. The tryptase serum levels were evaluated in 13 subjects suffering from allergic perennial rhinitis. Moreover the effects of cetirizine treatment on serum tryptase were studied using the UniCap™ tryptase fluoroenzymeimmunoassay. In allergic patients the serum tryptase values (M±SD: 6.1 ± 2.4 μg/L) were significantly (p < 0.02) higher than the values detected in controls (3.0 ± 1.2 μg/L). In allergic rhinitis, after antihistamine treatment, tryptase values (4.4 ± 1.8 μg/L) decreased significantly (p < 0.001). After two weeks from the cetirizine stop, the tryptase levels increased again (5.5 ± 2.6 μg/l). The results demonstrate that mast cells are constantly activated in perennial allergic rhinitis. The antihistamine treatment is effective in reducing the tryptase release from mast cells, but the mechanism of action of cetirizine is still to understand.

[1]  A. Luster,et al.  Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation , 1997, Journal of leukocyte biology.

[2]  J. Rowe-Jones.  The link between the nose and lung, perennial rhinitis and asthma—is it the same disease? , 1997, Allergy.

[3]  E. Meltzer.  The pharmacological basis for the treatment of perennial allergic rhinitis and non‐allergic rhinitis with topical corticosteroids , 1997, Allergy.

[4]  E. Charlesworth.  The role of basophils and mast cells in acute and late reactions in the skin , 1997, Chemical immunology.

[5]  R. Dahl,et al.  Epidemiology of allergic rhinitis , 1996, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[6]  S. Bonini,et al.  Tear tryptase levels and allergic conjunctivitis , 1996, Allergy.

[7]  G. Canonica,et al.  Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. , 1996, International archives of allergy and immunology.

[8]  P. Howarth,et al.  Allergic rhinitis: an increasing clinical problem , 1995, Allergy.

[9]  M. Masi,et al.  A placebo‐controlled trial of cetirizine in seasonal allergic rhino‐conjunctivitis in children aged 6 to 12 years , 1993, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[10]  A. Fitton,et al.  Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. , 1990, Drugs.

[11]  D. Broide,et al.  Airway levels of mast cell-derived mediators in exercise-induced asthma. , 1990, The American review of respiratory disease.

[12]  A. Kagey‐Sobotka,et al.  Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. , 1989, The Journal of allergy and clinical immunology.

[13]  L. Schwartz,et al.  Evaluation of human peripheral blood leukocytes for mast cell tryptase. , 1987, Journal of immunology.

[14]  T. Todisco.  Thoracoabdominal mechanics in dyspnea. , 1981, Respiration; international review of thoracic diseases.